Literature DB >> 3379036

Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine.

T Buhl1, L Thim, H Kofod, C Orskov, H Harling, J J Holst.   

Abstract

Recent studies have revealed that the glucagon gene is expressed in the mammalian intestine. Here it codes for "glicentin" (proglucagon 1-69) and a glucagon-like peptide, proglucagon 78-107, recently isolated from porcine intestine. We studied the fate of the remaining COOH-terminal part of proglucagon (proglucagon 111-160) using radioimmunoassays against proglucagon 111-123 and 126-160. Two peptides were isolated from acid ethanol extracts of porcine ileal mucosa and sequenced: one corresponding to proglucagon 126-158 and one probably corresponding to proglucagon 111-158. By comparing human and porcine proglucagon sequences, Ala117 is replaced by Thr, and Ile138, Ala144, Ile152 and Gln153 are replaced by Val, Thr, Leu, and His. By gel filtration and radioimmunoassay of intestinal extracts it was established that a large part of porcine and virtually all of human proglucagon are processed to release proglucagon 111-123 (designated spacer peptide 2), which, like proglucagon 126-158 must be considered a potential hormonal entity. By isocratic high pressure liquid chromatography human spacer peptide 2 was indistinguishable from synthetic proglucagon 111-122 amide, suggesting that this is the structure of the naturally occurring human peptide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3379036

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  Discovery, characterization, and clinical development of the glucagon-like peptides.

Authors:  Daniel J Drucker; Joel F Habener; Jens Juul Holst
Journal:  J Clin Invest       Date:  2017-12-01       Impact factor: 14.808

2.  Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

Authors:  D J Drucker; P Erlich; S L Asa; P L Brubaker
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

3.  Diabetic intestinal growth adaptation and glucagon-like peptide 2 in the rat: effects of dietary fibre.

Authors:  J Thulesen; B Hartmann; C Nielsen; J J Holst; S S Poulsen
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

4.  Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal--jejunal transposition or small bowel resection.

Authors:  J Thulesen; B Hartmann; H Kissow; P B Jeppesen; C Orskov; J J Holst; S S Poulsen
Journal:  Dig Dis Sci       Date:  2001-02       Impact factor: 3.199

Review 5.  Discovery of the GI Effects of GLP-1: An Historical Perspective.

Authors:  Jens Juul Holst
Journal:  Dig Dis Sci       Date:  2022-05-30       Impact factor: 3.487

6.  Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy.

Authors:  J Miholic; C Orskov; J J Holst; J Kotzerke; H J Meyer
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

7.  Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

Authors:  C Orskov; J Jeppesen; S Madsbad; J J Holst
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

8.  Peptide production and secretion in GLUTag, NCI-H716, and STC-1 cells: a comparison to native L-cells.

Authors:  Rune Ehrenreich Kuhre; Nicolai Jacob Wewer Albrechtsen; Carolyn Fiona Deacon; Emilie Balk-Møller; Jens Frederik Rehfeld; Frank Reimann; Fiona Mary Gribble; Jens Juul Holst
Journal:  J Mol Endocrinol       Date:  2016-01-27       Impact factor: 5.098

Review 9.  Actions of glucagon-like peptide-1 receptor ligands in the gut.

Authors:  Jens Juul Holst; Daniel Bjørklund Andersen; Kaare Villum Grunddal
Journal:  Br J Pharmacol       Date:  2021-08-04       Impact factor: 8.739

10.  Characterization and intracellular localization of putative Chlamydia pneumoniae effector proteins.

Authors:  Nicole Müller; Florian Sattelmacher; Raimond Lugert; Uwe Gross
Journal:  Med Microbiol Immunol       Date:  2008-05-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.